Novo Nordisk shares fall further as new CEO faces US challenges

Novo Nordisk shares plummeted over 25% in two days, erasing $70 billion in market value, after the company issued a profit warning and lowered its 2025 sales growth outlook due to unexpected competition from "compounded" copycat versions of its obesity drug Wegovy. The market's lack of confidence was exacerbated by incoming CEO Maziar Mike Doustdar's initial statements, leading analysts like Barclays to downgrade the stock, citing a "severe credibility issue," while JPMorgan cut its price target, reflecting continued investor caution despite Novo's efforts to address unlawful compounding.

Analysis

Novo Nordisk (NVO) is facing a significant crisis of confidence, precipitated by a profit warning that slashed its 2025 sales growth outlook. The stock's precipitous decline, which erased $70 billion in market value with a 22% drop on Tuesday followed by a further 3.1% fall, was triggered by management's disclosure of unexpectedly strong competition from "compounded" copycat versions of its flagship obesity drug, Wegovy. The situation was exacerbated by a perceived disconnect between the new CEO, Maziar Mike Doustdar, and market reality, with his comments on an investor call leading Barclays to cite a "severe credibility issue" and downgrade the stock to "equal-weight". While JPMorgan maintained an "overweight" rating, it sharply cut its price target from 650 to 500 crowns, signaling deep concern. The company's efforts to combat the issue through dialogue with the U.S. FDA are noted, but investor sentiment remains highly cautious, pending tangible evidence that management can execute on its new targets and successfully mitigate the competitive threat.

Key Decisions for Investors

• Investors should recognize that the severe stock price correction reflects fundamental headwinds from compounded drug competition and a management credibility deficit, not merely a transient market overreaction.
• Closely monitor near-term U.S. prescription data for Wegovy and any updates from the company or the U.S. FDA regarding efforts to curb unlawful compounding, as these are the primary catalysts for a potential recovery.
• It may be prudent to await evidence of execution against the new, lower growth targets and signs of restored investor confidence before considering new or increasing existing long positions, aligning with the cautious stance of analysts.